US Chamber Backs Amgen In FTC's $27.8B Merger Challenge

By Renee Hickman · August 29, 2023, 9:31 PM EDT

The U.S. Chamber of Commerce is backing biotechnology company Amgen in its bid to complete a $27.8 billion merger with Horizon Therapeutics, saying in an amicus brief Tuesday that if the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Motion

Case Information

Case Title

Federal Trade Commission V. Amgen Inc., et al.

Case Number

Court

Illinois Northern

Nature of Suit

410(Anti-Trust)

Date Filed

May 16, 2023

Recent Articles By Renee

February 14, 2024
Adagio Medical Goes Public In $128M SPAC Merger
February 12, 2024
Assure Buys Danam Health To Form $150M Business
February 06, 2024
McDermott-Led 3 Boomerang Nabs $375M For Debut Fund
September 27, 2023
Avalyn Pharma Raises $175M In Series C Financing Round
September 14, 2023
Abcam Founder Opposes Danaher Deal, Wants Board Gone
August 18, 2023
4 Firms Guide SPAC Deal For $300M Pregnancy Care Co. Nuvo
August 14, 2023
Life Sciences Biz Paying Up To $200M For CBD Drugmaker
August 07, 2023
Estia Health Gives Thumbs Up To AU$838M PE Takeover Bid
July 28, 2023
Tivity Appeals Nutrisystem Merger Investor Class Cert, Again
July 17, 2023
FTC Moves To Block IQVIA Deal Over Health Ad Concerns